Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review

The objective was to evaluate the comparative effectiveness and safety of pharmacological and nonpharmacological management options for atrial fibrillation/atrial flutter with rapid ventricular response (AFRVR) in patients with acute decompensated heart failure (ADHF) in the acute care setting.

[1]  J. Parissis,et al.  The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature , 2022, European heart journal supplements : journal of the European Society of Cardiology.

[2]  T. Shiga.  Benefits and safety of landiolol for rapid rate control in patients with atrial tachyarrhythmias and acute decompensated heart failure , 2022, European heart journal supplements : journal of the European Society of Cardiology.

[3]  Tammy T Nguyen,et al.  Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department. , 2022, The American journal of emergency medicine.

[4]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[5]  D. Carrié,et al.  Successful Reversal of Severe Tachycardia-Induced Cardiomyopathy with Cardiogenic Shock by Urgent Rhythm or Rate Control: Only Rhythm and Rate Matter , 2021, Journal of clinical medicine.

[6]  D. Harrison,et al.  Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review , 2021, Critical Care.

[7]  J. Healey,et al.  The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. , 2020, The Canadian journal of cardiology.

[8]  Roger Suss.  Guideline groups should not make recommendations when there is considerable uncertainty , 2020, Canadian Medical Association Journal.

[9]  Julian Pt Higgins,et al.  Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments , 2020, Research synthesis methods.

[10]  R. Sinert,et al.  Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department: A Systematic Review and Network Meta-analysis. , 2020, Annals of emergency medicine.

[11]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[12]  E. Belley‐Cote,et al.  New-onset atrial fibrillation in adult critically ill patients: a scoping review , 2019, Intensive Care Medicine.

[13]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.

[14]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.

[15]  G. Peksa,et al.  Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction☆,☆☆ , 2019, The American journal of emergency medicine.

[16]  M. Jandali.  Safety of Intravenous Diltiazem in Reduced Ejection Fraction Heart Failure with Rapid Atrial Fibrillation , 2018, Clinical Drug Investigation.

[17]  J. Healey,et al.  Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation , 2018 .

[18]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[19]  J. Healey,et al.  2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. , 2016, The Canadian journal of cardiology.

[20]  J. Piccini,et al.  Atrial fibrillation in heart failure: what should we do? , 2015, European heart journal.

[21]  R. Califf,et al.  Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial , 2015, Journal of the American Heart Association.

[22]  B. Rowe,et al.  Emergency Department Patients With Atrial Fibrillation or Flutter and an Acute Underlying Medical Illness May Not Benefit From Attempts to Control Rate or Rhythm. , 2015, Annals of emergency medicine.

[23]  M. Giudici,et al.  EFFICACY AND SAFETY OUTCOMES OF VARIOUS RATE CONTROL STRATEGIES FOR PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE WITH REDUCED EJECTION FRACTION AND ATRIAL FIBRILLATION OR FLUTTER WITH RAPID VENTRICULAR RESPONSE , 2015 .

[24]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[25]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[26]  Deepak L. Bhatt,et al.  Presence of Atrial Fibrillation Is Independently Associated With Adverse Outcomes in Patients Hospitalized With Heart Failure: An Analysis of Get With The Guidelines–Heart Failure , 2012, Circulation. Heart failure.

[27]  S. Evans.  Clinical trial structures. , 2010, Journal of experimental stroke & translational medicine.

[28]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[29]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[30]  Amin Daoulah,et al.  Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. , 2007, The American journal of cardiology.

[31]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[32]  L. Tamariz,et al.  Pharmacological rate control of atrial fibrillation. , 2004, Cardiology clinics.

[33]  A. Manolis,et al.  Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. , 2001, International journal of cardiology.

[34]  Marlene R. Miller,et al.  The evidence regarding the drugs used for ventricular rate control. , 2000, The Journal of family practice.

[35]  J. Grimshaw,et al.  Potential benefits, limitations, and harms of clinical guidelines , 1999, BMJ.

[36]  W. Lewis,et al.  Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. , 1994, The American journal of cardiology.

[37]  A. Zbrozek,et al.  Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. , 1993, The American journal of cardiology.